These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8103781)

  • 1. Dopaminergic resistance in a case of invasive macroprolactinoma.
    Schwarzstein D; García-Patterson A; Giménez G; Calaf J; Puig-Domingo M; Caixàs A; Matías-Guiu X; Webb SM
    J Endocrinol Invest; 1993 Jun; 16(6):443-7. PubMed ID: 8103781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The best approach to treat prolactinoma].
    Zárate A; Saucedo R; Basurto L
    Gac Med Mex; 2004; 140(5):567-9. PubMed ID: 15559242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of micro- and macroprolactinoma. Must dopamine agonists be given lifelong?].
    von Werder K
    Dtsch Med Wochenschr; 1991 Jan; 116(1):25-7. PubMed ID: 1670764
    [No Abstract]   [Full Text] [Related]  

  • 4. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A clinical analysis of 103 male patients with macroprolactinoma].
    Xu J; Jin ZM; Deng JY; Wu QY; Shi YF
    Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):356-9. PubMed ID: 16009006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystic degeneration of macroprolactinoma on long-term cabergoline.
    Sharif DA; Nkonge FM; Chawda S; Benjamin J; Stojanović ND
    J Clin Endocrinol Metab; 2010 Aug; 95(8):3593-4. PubMed ID: 20685886
    [No Abstract]   [Full Text] [Related]  

  • 7. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
    Meyer P; Bohnen NI; Barkan AL; Shapiro B
    Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CV205-502, a new non-ergot dopamine agonist, reduces prolactinoma size in man.
    Barnett PS; Dawson JM; Butler J; Coskeran PB; Maccabe JJ; McGregor AM
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):307-16. PubMed ID: 1977537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma.
    Del Gatto V; Bima C; Chiloiro S; Giampietro A; Bianchi A
    Endocrine; 2018 Jun; 60(3):532-534. PubMed ID: 29214441
    [No Abstract]   [Full Text] [Related]  

  • 10. CV 205-502 treatment of macroprolactinomas.
    Crottaz B; Uske A; Reymond MJ; Rey F; Siegel RA; Brownell J; Gomez F
    J Endocrinol Invest; 1991 Oct; 14(9):757-62. PubMed ID: 1684803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine.
    van der Lely AJ; Brownell J; Lamberts SW
    J Clin Endocrinol Metab; 1991 May; 72(5):1136-41. PubMed ID: 1673685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 15-year-old boy with ocular palsy and headache. Invasive macroprolactinoma.
    Minniti G; Jaffrain-Rea ML; Lunardi P; Gulino A; Tamburrano G
    Eur J Pediatr; 1996 Aug; 155(8):717-9. PubMed ID: 8839732
    [No Abstract]   [Full Text] [Related]  

  • 13. Nerve growth factor controls proliferation and progression of human prolactinoma cell lines through an autocrine mechanism.
    Missale C; Losa M; Sigala S; Balsari A; Giovanelli M; Spano PF
    Mol Endocrinol; 1996 Mar; 10(3):272-85. PubMed ID: 8833656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline treatment in a case of macroprolactinoma after delivery.
    Falsetti L
    Acta Eur Fertil; 1995; 26(3):105-7. PubMed ID: 9098469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macroprolactinoma expansion during pregnancy.
    Trivedi N; Mithal A
    J Assoc Physicians India; 1993 Nov; 41(11):738-9. PubMed ID: 8005934
    [No Abstract]   [Full Text] [Related]  

  • 16. Giant prolactinomas: Multi-modal approach to achieve tumor control.
    Shimon I
    Endocrine; 2017 May; 56(2):227-228. PubMed ID: 28050685
    [No Abstract]   [Full Text] [Related]  

  • 17. Aggressive pituitary macroadenoma: CT and MR appearances.
    Van de Straete S; Githeko J; Demaerel P; Wilms G; Lammens M; Plets C; Bouillon R; Baert AL
    J Belge Radiol; 1996 Dec; 79(6):255-7. PubMed ID: 9031535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topiramate Overcoming Dopamine Agonist-Induced Migraine Exacerbation and Avoiding Transsphenoidal Surgery in a Young Boy With a Macroprolactinoma.
    Faria AM; de F Presti P; Damiani D; Musolino NR; Neto MB
    Headache; 2016 Oct; 56(9):1507-1511. PubMed ID: 27400437
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prolactinoma is more frequent among men than among women. A dopamine agonist is effective in the treatment].
    Hulting AL; Muhr C; Lundberg PO; Werner S
    Lakartidningen; 1990 Dec; 87(50):4335-7. PubMed ID: 1980709
    [No Abstract]   [Full Text] [Related]  

  • 20. Disappearance of a pituitary tumor after 15 months of treatment with CV 205-502, a new dopamine agonist.
    Fassbender WJ; Stracke H; Bachmann G; Rau W; Federlin K
    Clin Investig; 1992 May; 70(5):444-6. PubMed ID: 1350936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.